Mar 07 |
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Ca...
First-ever HPV16-positive head and neck cancer... |
Feb 27 |
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules...
$11 Million Upfront with up to an Additional $11... |
Feb 26 |
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metas...
Median Overall Survival (mOS) of 42.4 months in... |
Feb 24 |
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer...
Data confirms Versamune® HPV has potential as a... |
Feb 20 |
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025...
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS... |
Feb 05 |
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Re...
FDA-cleared amended trial design; First site... |